Compare PGNY & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGNY | WGS |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.7B |
| IPO Year | 2019 | 2020 |
| Metric | PGNY | WGS |
|---|---|---|
| Price | $29.54 | $63.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $34.42 | ★ $93.50 |
| AVG Volume (30 Days) | ★ 890.5K | 746.0K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.04 | ★ 62.37 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $1,288,661,000.00 | $427,539,000.00 |
| Revenue This Year | $6.64 | $12.70 |
| Revenue Next Year | $10.16 | $24.31 |
| P/E Ratio | $46.32 | ★ N/A |
| Revenue Growth | 10.40 | ★ 39.97 |
| 52 Week Low | $16.10 | $32.21 |
| 52 Week High | $33.07 | $170.87 |
| Indicator | PGNY | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 44.05 |
| Support Level | $24.89 | $56.09 |
| Resistance Level | $33.07 | $73.04 |
| Average True Range (ATR) | 0.80 | 5.71 |
| MACD | 0.12 | 0.84 |
| Stochastic Oscillator | 96.36 | 54.92 |
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.